This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
June 13, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook GSK’s vaccine leverages GMMA technology. GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for continued development and distribution in low and middle-income nations. Can pharma tariffs “Make America Manufacture Again”?
A novel approach for ensuring the virtually unlimited production of QS-21, the ‘Gold Standard’ adjuvant for improving vaccine efficacy, will be the subject of an upcoming presentation at the BIO CEO & Investor Digital Conference, starting February 16.
For years, the promise of therapeutic cancer vaccines has intrigued researchers working in the oncology space. The concept of pre-emptively training the immune system to increase the frequencies of tumour-reactive T cells could be game-changing for cancer patients worldwide. And for good reason.
Find out more This treatment involves obtaining immune cells from patients, modifying them in a laboratory setting then reintroducing them into patients’ bodies to destroy cancerous cells. Can pharma tariffs “Make America Manufacture Again”? Data Insights The gold standard of business intelligence.
US Health Secretary Robert F Kennedy (RFK) Jr has appointed eight new members to the vaccine advisory panel at the Centers for Disease Control and Prevention (CDC), just days after firing the panel’s previous members in full. Can pharma tariffs “Make America Manufacture Again”? Credit: LightRocket via Getty Images. Who’s on the panel?
CD4+T-cells and lymphocytes are both crucial elements of the immune system. Can pharma tariffs “Make America Manufacture Again”? Low levels of either increase the likelihood of infections and other health problems. HIV itself can reduce CD4 count – a value lower than 200 indicates acquired immunodeficiency syndrome (AIDS).
A low incidence of immune effector cell-associated neurotoxicity syndrome was reported during the step-up dosing phase and the target dose phase. Can pharma tariffs “Make America Manufacture Again”? Two patients experienced dose-limiting toxicities and continued to receive the targeted dose.
By GlobalData Learn more about Strategic Intelligence FDA’s strategy on trial designs, vaccines and manufacturing Earlier this month, when the Department of Health and Human Sciences Secretary Robert Kennedy Jr. Can pharma tariffs “Make America Manufacture Again”?
In the last few years, the first generation of cell therapies has offered a powerful new way of treating blood cancers, with CAR-T technology reprogramming patients’ immune system to fight cancer. The post After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer appeared first on.
The first mRNA drug (BNT162b2 vaccine) was granted emergency use authorization by the FDA in December 2020 and approved for marketing in August 2021. The first mRNA drug (BNT162b2 vaccine) was granted emergency use authorization by the FDA in December 2020 and approved for marketing in August 2021.
Birthplace: Belén was born in Almansa (Spain) Additional Information: Merck became a significant international participant in immunology, oncology, and immune oncology under her leadership of the Healthcare business. Designation: Global Head Previous company: Merck Global Vaccines (2 yrs. and Banco Bilbao Vizcaya Argentaria S.A
While restrictions on travel could prevent coronavirus transmission in the short term, digital passports showing COVID-negative and vaccination status may help reopen airports and other badly hit areas of the economy, reports Richard Staines. But could digital immunity passports be the answer?
Keytruda is designed to enhance the immune system’s ability to detect and combat tumour cells. Can pharma tariffs “Make America Manufacture Again”? Based on these trial results, Keytruda as part of this regimen shows potential to change long-standing standards of care for treating certain patients with locally advanced HNSCC.”
New York Magazine , the New York Times and The Economist amongst many other news organisations knocked down their paywalls for COVID-19-related coverage to keep readers informed in a rapidly changing and often confusing environment. Think you need to build manufacturing of a vaccine before you know what’s working.
Robert Barrie June 13, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook mRESVIA is the second approved product in the US for Moderna, along with its Covid-19 vaccine Spikevax. Until now, the vaccine was licensed for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 years and older.
George Merck on the cover of Time magazine. In cancer, the pharma industry has begun producing immunotherapies, which do not act directly against the disease but instead enlist the immune system to fight against malignant tissues. Thalidomide and the development of drug safety regulation and monitoring.
Robert Barrie and Ross Law June 10, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The removal ACIP members marks the most significant upheaval to the current vaccine landscape under Trump’s administration. Can pharma tariffs “Make America Manufacture Again”? lev radin via Shutterstock. lev radin via Shutterstock.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content